These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 29957591

  • 1. Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma.
    Kurosawa M, Sutoh E.
    J Investig Allergol Clin Immunol; 2019; 29(1):40-45. PubMed ID: 29957591
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
    Pelaia C, Busceti MT, Solinas S, Terracciano R, Pelaia G.
    Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
    [Abstract] [Full Text] [Related]

  • 6. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
    Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y, Humbert M, Castro M, Marsteller DA, McElhattan J, Hickey L, Garin M, Vanlandingham R, Brusselle G.
    Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
    [Abstract] [Full Text] [Related]

  • 7. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
    Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H.
    J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A.
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [Abstract] [Full Text] [Related]

  • 9. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M, Albers FC, Bratton DJ, Yancey SW, Liu MC, Hozawa S, Llanos JP, Kwon N.
    Respir Med; 2019 May; 154():69-75. PubMed ID: 31220806
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE, Chaudhuri R, Pavord ID, Heaney LG, Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium).
    Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
    [Abstract] [Full Text] [Related]

  • 13. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M.
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
    Gunsoy NB, Cockle SM, Yancey SW, Keene ON, Bradford ES, Albers FC, Pavord ID.
    J Allergy Clin Immunol Pract; 2018 May; 6(3):874-882.e4. PubMed ID: 29258789
    [Abstract] [Full Text] [Related]

  • 15. Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience.
    Lim YT, Williams TC, Langley RJ, Weir E.
    J Asthma; 2024 Aug; 61(8):793-800. PubMed ID: 38240489
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T, Odajima H, Okamasa A, Kawase M, Komatsubara M, Mayer B, Yancey S, Ortega H.
    Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
    [Abstract] [Full Text] [Related]

  • 17. Favorable clinical efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma: a 48-week pilot study.
    Kurosawa M, Ogawa E, Sutoh E.
    Eur Ann Allergy Clin Immunol; 2019 Sep 16; 51(5):213-221. PubMed ID: 30983308
    [Abstract] [Full Text] [Related]

  • 18. A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab.
    Terashima T, Shinozaki T, Iwami E, Nakajima T, Matsuzaki T.
    BMC Pulm Med; 2018 Mar 27; 18(1):53. PubMed ID: 29587693
    [Abstract] [Full Text] [Related]

  • 19. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype.
    Pelaia C, Crimi C, Pelaia G, Nolasco S, Campisi R, Heffler E, Valenti G, Crimi N.
    Clin Exp Allergy; 2020 Jul 27; 50(7):780-788. PubMed ID: 32347992
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
    Gupta A, Ikeda M, Geng B, Azmi J, Price RG, Bradford ES, Yancey SW, Steinfeld J.
    J Allergy Clin Immunol; 2019 Nov 27; 144(5):1336-1342.e7. PubMed ID: 31425781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.